References
Almadrones, L., McGuire, D. B., Walczak, J. R., Florio, C. M., & Tian, C. (2004). Psychometric evaluation of two scales assessing functional status and peripheral neuropathy associated with chemotherapy for ovarian cancer. Oncology Nursing Forum, 31, 615-623.
Armstrong, T., Almadrones, L., & Gilbert, M. R. (2005). Chemotherapy-induced peripheral neuropathy. Oncology Nursing Forum, 32, 305-311.
Bakitas, M. A. (2007). Background noise: The experience of chemotherapy-induced peripheral neuropathy. Nursing Research, 56, 323-331.
Bril, V. (1999). The primary measurement scale for clinical trial endpoints in diabetic peripheral neuropathy. European Neurology, 41(Suppl. 1), 8-13. doi: 10.1159/000052074
Calhoun, E. A., Welshman, E. E., Chang, C. H., Lurain, J. R., Fishman, D. A., Hunt, T. L., & Cella, D. (2003). Psychometric evaluation of the Functional Assessment of Cancer Therapy-Gynecologic Oncology Group/Neurotoxicity questionnaire for patients receiving systemic chemotherapy. International Journal of Gynecological Cancer, 13, 741-748.
Cavaletti, G., Bogliun, G., Marzorati, L., Zincone, A., Piatti, M., Colombo, N., … Zanna, C. (2003). Grading of chemotherapy-induced peripheral neurotoxicity using the total neuropathy scale. Neurology, 61, 1297-1300.
Cavaletti, G., Jann, S., Pace, A., Plasmati, R., Siciliano, G., Briani, C., … Giussani, G. (2006). Multi-center assessment of the total neuropathy score for chemotherapy-induced peripheral neurotoxicity. Journal of the Peripheral Nervous System, 11, 135-141.
Cavaletti, G., Tredici, G., Petruccioli, M. G., Donde, E., Tredici, P., Marmiroli, P., … Etienne, G. G. (2001). Effects of different schedules of oxaliplatin treatment on the peripheral nervous system of the rat. European Journal of Cancer, 37, 2457-2463. doi: 10.1016/S0959-8049 (01)00300-8
Cella, D., Peterman, A., Hudgens, S., Webster, K., & Socinski, M. A. (2003). Measuring the side effects of taxane therapy in oncology: The Functional Assessment of Cancer Therapy-Taxane (FACT-Taxane). Cancer, 98, 822-831. doi: 10.1002/cncr.11578
Chaudhry, V., Cornblath, D. R., Corse, A., Freimer, M., Simmons-O'Brien, E., & Vogelsang, G. (2002). Thalidomide-induced neuropathy. Neurology, 59, 1872-1875.
Chaudhry, V., Eisenberger, M. A., Sinibaldi, V. J., Sheikh, K., Griffin, J. W., & Cornblath, D. R. (1996). A prospective study of suramin-induced peripheral neuropathy. Brain, 119(Pt. 6), 2039-2052.
Chaudhry, V., Rowinsky, E. K., Sartorius, S. E., Donehower, R. C., & Cornblath, D. R. (1994). Peripheral neuropathy from taxol and cisplatin combination chemotherapy: Clinical and electrophysiological studies. Annals of Neurology, 35, 304-311. doi: 10.1002/ana.410350310
Dyck, P. J., Karnes, J., O'Brien, P. C., & Swanson, C. J. (1986). Neuropathy symptom profile in health, motor neuron disease, diabetic neuropathy, and amyloidosis. Neurology, 36, 1300-1308.
Elderly Lung Cancer Vinorelbine Italian Study Group. (1999). Effects of vinorelbine on quality of life and survival of elderly patients with advanced non-small-cell lung cancer. Journal of the National Cancer Institute, 91, 66-72. doi: 10.1093/jnci/91.1.66
England, J. D., Gronseth, G. S., Franklin, G., Miller, R. G., Asbury, A. K., Carter, G. T., … Sumner, A. J. (2005). Distal symmetric polyneuropathy: A definition for clinical research. Neurology, 64, 199-207.
Feldman, E., & Stevens, M. (1994). Clinical testing in diabetic peripheral neuropathy. Canadian Journal of Neurological Sciences, 21(4), S3-S7.
Franse, L. V., Valk, G. D., Dekker, J. H., Heine, R. J., & van Eijk, J. T. (2000). ‘Numbness of the feet’ is a poor indicator for polyneuropathy in type 2 diabetic patients. Diabetic Medicine, 17, 105-110.
Galer, B. S., & Jensen, M. P. (1997). Development and preliminary validation of a pain measure specific to neuropathic pain: The Neuropathic Pain Scale. Neurology, 48, 332-338.
Gregg, R. W., Molepo, J. M., Monpetit, V. J., Mikael, N. Z., Redmond, D., Gadia, M., & Stewart, D. J. (1992). Cisplatin neurotoxicity: The relationship between dosage, time, and platinum concentration in neurologic tissues, and morphologic evidence of toxicity. Journal of Clinical Oncology, 10, 795-803.
Hagiwara, H., & Sunada, Y. (2004). Mechanism of taxane neurotoxicity. Breast Cancer, 11, 82-85. doi: 10.1007/BF02968008
Hausheer, F. H., Schilsky, R. L., Bain, S., Berghorn, E. J., & Lieberman, F. (2006). Diagnosis, management, and evaluation of chemotherapy-induced peripheral neuropathy. Seminars in Oncology, 33, 15-49.
Hilkens, P. H., & ven den Bent, M. J. (1997). Chemotherapy-induced peripheral neuropathy. Journal of the Peripheral Nervous System, 2, 350-361.
Hilkens, P. H., Verweij, J., Stoter, G., Vecht, C. J., van Putten, W. L., & van den Bent, M. J. (1996). Peripheral neurotoxicity induced by docetaxel. Neurology, 46, 104-108.
Jensen, M. P., Gammaitoni, A. R., Olaleye, D. O., Oleka, N., Nalamachu, S. R., & Galer, B. S. (2006). The Pain Quality Assessment Scale: Assessment of pain quality in carpal tunnel syndrome. Journal of Pain, 7, 823-832. doi: 10.1016/j.jpain.2006.04.003
Kopec, J. A., Land, S. R., Cecchini, R. S., Ganz, P. A., Cella, D., Costantino, J. P., … Wolmark, N. (2006). Validation of a self-reported neurotoxicity scale in patients with operable colon cancer receiving oxaliplatin. Supportive Oncology, 4(8), W1-W8.
Kuroi, K., Shimozuma, K., Ohashi, Y., Hisamatsu, K., Masuda, N., Takeuchi, A., … Hausheer, F. H. (2009). Prospective assessment of chemotherapy-induced peripheral neuropathy due to weekly paclitaxel in patients with advanced or metastatic breast cancer (CSP-HOR 02 study). Supportive Care in Cancer, 17, 1071-1080.
Markman, M., Kennedy, A., Webster, K., Kulp, B., Peterson, G., & Belinson, J. (2001). Neurotoxicity associated with a regimen of carboplatin (AUC 5-6) and paclitaxel (175 mg/m2 over 3 h) employed in the treatment of gynecologic malignancies. Journal of Cancer Research and Clinical Oncology, 127, 55-58. doi: 10.1007/s004320000157
Ocean, A. J., & Vahdat, L. T. (2004). Chemotherapy-induced peripheral neuropathy: Pathogenesis and emerging therapies. Supportive Care in Cancer, 12, 619-625.
Ostchega, Y., Donohue, M., & Fox, N. (1988). High-dose cisplatin-related peripheral neuropathy. Cancer Nursing, 11, 23-32.
Postma, T. J., Aaronson, N. K., Heimans, J. J., Muller, M. J., Hildebrand, J. G., Delattre, J. Y., … Lucey, R. (2005). The development of an EORTC quality of life questionnaire to assess chemotherapy-induced peripheral neuropathy: The QLQ-CIPN20. European Journal of Cancer, 41, 1135-1139. doi: 10.1016/j.ejca.2005.02.012
Postma, T. J., & Heimans, J. J. (1997). Chemotherapy-induced peripheral neuropathy. In P. J. Vecht, G. W. Bruyn, & K. E. Davis (Eds.), Handbook of clinical neurology: Neuro-oncology, part III (pp. 459-479). Amsterdam, Netherlands: Elsevier Sciences.
Postma, T. J., Heimans, J. J., Muller, M. J., Ossenkoppele, G. J., Vermorken, J. B., & Aaronson, N. K. (1998). Pitfalls in grading severity of chemotherapy-induced peripheral neuropathy. Annals of Oncology, 9, 739-744. doi: 10.1023/A:1008344507482
Russell, J. W., Windebank, A. J., McNiven, M. A., Brat, D. J., & Brimijoin, W. S. (1995). Effect of cisplatin and ACTH4-9 on neural transport in cisplatin induced neurotoxicity. Brain Research, 676, 258-267.
Screnci, D., & McKeage, M. J. (1999). Platinum neurotoxicity: Clinical profiles, experimental models and neuroprotective approaches. Journal of Inorganic Biochemistry, 77(1-2), 105-110.
Smith, E. (2008). Clinimetric evaluation of peripheral neuropathy measurement approaches. University of Utah, 123 p-123 p. (UMI Order: AAI3302494.)
Smith, E. L., Beck, S. L., & Cohen, J. (2008). The total neuropathy score: A tool for measuring chemotherapy-induced peripheral neuropathy. Oncology Nursing Forum, 35, 96-102. doi: 10.1188/08.ONF.96-102
Smith, E. L., Cohen, J. A., Pett, M. A., & Beck, S. L. (2009). The reliability and validity of a modified Total Neuropathy Score-reduced (TNSr) and neuropathic pain severity items when used to measure chemotherapy-induced peripheral neuropathy in patients receiving taxanes and platinums. Cancer Nursing, 33, 173-183.
Sweeney, C. W. (2002). Understanding peripheral neuropathy in patients with cancer: Background and patient assessment. Clinical Journal of Oncology Nursing, 6, 163-166.
Verstappen, C. C., Heimans, J. J., Hoekman, K., & Postma, T. J. (2003). Neurotoxic complications of chemotherapy in patients with cancer: Clinical signs and optimal management. Drugs, 63, 1549-1563.
Vileikyte, L., Peyrot, M., Bundy, C., Rubin, R. R., Leventhal, H., Mora, P., … Boulton, J. M. (2003). The development and validation of a neuropathy- and foot ulcer-specific quality of life instrument. Diabetes Care, 26, 2549-2555. doi: 10.2337/diacare.26.9.2549
Visovsky, C. (2003). Chemotherapy-induced peripheral neuropathy. Cancer Investigation, 21, 439-451. doi: 10.1081/CNV-120018236
Wampler, M. A., Miaskowski, C., Hamel, K., Byl, N., Rugo, H., & Topp, L. S. (2006). The modified total neuropathy score: A clinically feasible and valid measure of taxane-induced peripheral neuropathy in women with breast cancer. Supportive Oncology, 4(8), W9-W16.
Wickham, R. (2007). Chemotherapy-induced peripheral neuropathy: A review and implications for oncology nursing practice. Clinical Journal of Oncology Nursing, 11, 361-376. doi: 10.1188/07.CJON.361-376